Notice of Changes in Accounting Period (End of Business Year)

Tokyo, Japan and London, UK, 10 May 2018 – Sosei Group Corporation ("Sosei") today announced that its Board of Directors has resolved to change the fiscal year-end, subject to the approval of the "Proposal for partial amendment to the Articles of Incorporation" at the 28th Ordinary General Meeting of Shareholders to be held on in June, 2018.

1. Reason for Change
The Company is aligning its fiscal year end to be in line with our Global peer group including the major pharmaceutical companies that we partner and collaborate with on a global basis.

2. Details of change in fiscal year-end
(1) Current Accounting Period: As of March 31 of each year
(2) After the change: December 31 of each year

Note: The 29th fiscal year, the transitional period for the change in fiscal year-end, will be nine months from April 1, 2018 to December 31, 2018.

3. Future Outlook
Please refer to future outlook in the summary of earnings report for FY2017 disclosed today.

4. Amendment to Articles of Incorporation
We will disclose the "Proposal for amendment to the Articles of Incorporation" promptly after the proposal is determined at the board of directors meeting scheduled for May 15, 2018 as part of the proposals to be submitted to the 28th Annual General Meeting of Shareholders to be held in June 2018.

Enquiries:

Sosei +44 (0) 7912 892 199
Chris Cargill, Head of Investor Relations and Corporate Communications

Citigate Dewe Rogerson (media advisor) +44 (0) 20 7638 9571
David Dible
Mark Swallow

About Sosei Group Corporation
Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit http://www.sosei.com/en/.